JP2011519832A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011519832A5 JP2011519832A5 JP2011505549A JP2011505549A JP2011519832A5 JP 2011519832 A5 JP2011519832 A5 JP 2011519832A5 JP 2011505549 A JP2011505549 A JP 2011505549A JP 2011505549 A JP2011505549 A JP 2011505549A JP 2011519832 A5 JP2011519832 A5 JP 2011519832A5
- Authority
- JP
- Japan
- Prior art keywords
- methoxy
- benzamide
- phenyl
- amino
- thioxomethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- VKPLPDIMEREJJF-UHFFFAOYSA-N 3-methoxybenzamide Chemical compound COC1=CC=CC(C(N)=O)=C1 VKPLPDIMEREJJF-UHFFFAOYSA-N 0.000 claims 144
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 111
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 109
- 125000000043 benzamido group Chemical group [H]N([*])C(=O)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 58
- -1 polycyclic hydrocarbon Chemical class 0.000 claims 52
- CFHIDWOYWUOIHU-UHFFFAOYSA-N oxomethyl Chemical group O=[CH] CFHIDWOYWUOIHU-UHFFFAOYSA-N 0.000 claims 21
- 150000001875 compounds Chemical class 0.000 claims 16
- 125000000217 alkyl group Chemical group 0.000 claims 12
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 12
- VHBTUNPEVBMRRY-UHFFFAOYSA-N n-[[3-(1h-benzimidazol-2-yl)-4-methylphenyl]carbamothioyl]-3,4,5-trimethoxybenzamide Chemical compound COC1=C(OC)C(OC)=CC(C(=O)NC(=S)NC=2C=C(C(C)=CC=2)C=2NC3=CC=CC=C3N=2)=C1 VHBTUNPEVBMRRY-UHFFFAOYSA-N 0.000 claims 12
- FJNOMPZPFBXDRQ-UHFFFAOYSA-N 3,4,5-trimethoxy-n-[[3-[(4-phenylphenyl)carbamoylamino]phenyl]carbamothioyl]benzamide Chemical compound COC1=C(OC)C(OC)=CC(C(=O)NC(=S)NC=2C=C(NC(=O)NC=3C=CC(=CC=3)C=3C=CC=CC=3)C=CC=2)=C1 FJNOMPZPFBXDRQ-UHFFFAOYSA-N 0.000 claims 10
- 125000002950 monocyclic group Chemical group 0.000 claims 10
- 125000003545 alkoxy group Chemical group 0.000 claims 9
- 125000005843 halogen group Chemical group 0.000 claims 9
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 239000001257 hydrogen Substances 0.000 claims 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- 125000004414 alkyl thio group Chemical group 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 6
- 125000005010 perfluoroalkyl group Chemical group 0.000 claims 6
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 125000000623 heterocyclic group Chemical group 0.000 claims 5
- 125000003367 polycyclic group Chemical group 0.000 claims 5
- 229910052717 sulfur Inorganic materials 0.000 claims 5
- 125000004434 sulfur atom Chemical group 0.000 claims 5
- 230000003902 lesion Effects 0.000 claims 4
- 230000000626 neurodegenerative effect Effects 0.000 claims 4
- 125000002560 nitrile group Chemical group 0.000 claims 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims 4
- 239000011593 sulfur Substances 0.000 claims 4
- 239000004215 Carbon black (E152) Substances 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 125000004432 carbon atom Chemical group C* 0.000 claims 3
- 125000004663 dialkyl amino group Chemical group 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229930195733 hydrocarbon Natural products 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 229920006395 saturated elastomer Polymers 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 3
- VIJSPAIQWVPKQZ-BLECARSGSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-4,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O VIJSPAIQWVPKQZ-BLECARSGSA-N 0.000 claims 2
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 claims 2
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 claims 2
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 claims 2
- FMKGJQHNYMWDFJ-CVEARBPZSA-N 2-[[4-(2,2-difluoropropoxy)pyrimidin-5-yl]methylamino]-4-[[(1R,4S)-4-hydroxy-3,3-dimethylcyclohexyl]amino]pyrimidine-5-carbonitrile Chemical compound FC(COC1=NC=NC=C1CNC1=NC=C(C(=N1)N[C@H]1CC([C@H](CC1)O)(C)C)C#N)(C)F FMKGJQHNYMWDFJ-CVEARBPZSA-N 0.000 claims 2
- LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 claims 2
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 claims 2
- WYFCZWSWFGJODV-MIANJLSGSA-N 4-[[(1s)-2-[(e)-3-[3-chloro-2-fluoro-6-(tetrazol-1-yl)phenyl]prop-2-enoyl]-5-(4-methyl-2-oxopiperazin-1-yl)-3,4-dihydro-1h-isoquinoline-1-carbonyl]amino]benzoic acid Chemical compound O=C1CN(C)CCN1C1=CC=CC2=C1CCN(C(=O)\C=C\C=1C(=CC=C(Cl)C=1F)N1N=NN=C1)[C@@H]2C(=O)NC1=CC=C(C(O)=O)C=C1 WYFCZWSWFGJODV-MIANJLSGSA-N 0.000 claims 2
- GUCPYIYFQVTFSI-UHFFFAOYSA-N 4-methoxybenzamide Chemical compound COC1=CC=C(C(N)=O)C=C1 GUCPYIYFQVTFSI-UHFFFAOYSA-N 0.000 claims 2
- XFJBGINZIMNZBW-CRAIPNDOSA-N 5-chloro-2-[4-[(1r,2s)-2-[2-(5-methylsulfonylpyridin-2-yl)oxyethyl]cyclopropyl]piperidin-1-yl]pyrimidine Chemical compound N1=CC(S(=O)(=O)C)=CC=C1OCC[C@H]1[C@@H](C2CCN(CC2)C=2N=CC(Cl)=CN=2)C1 XFJBGINZIMNZBW-CRAIPNDOSA-N 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 102000003693 Hedgehog Proteins Human genes 0.000 claims 2
- 108090000031 Hedgehog Proteins Proteins 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 208000026072 Motor neurone disease Diseases 0.000 claims 2
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims 2
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 claims 2
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 claims 2
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 claims 2
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 229940125904 compound 1 Drugs 0.000 claims 2
- 229940125782 compound 2 Drugs 0.000 claims 2
- 229940125810 compound 20 Drugs 0.000 claims 2
- 229940126086 compound 21 Drugs 0.000 claims 2
- 229940125833 compound 23 Drugs 0.000 claims 2
- 229940125961 compound 24 Drugs 0.000 claims 2
- 229940125846 compound 25 Drugs 0.000 claims 2
- 229940126214 compound 3 Drugs 0.000 claims 2
- 229940127573 compound 38 Drugs 0.000 claims 2
- 229940126545 compound 53 Drugs 0.000 claims 2
- 229940127113 compound 57 Drugs 0.000 claims 2
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 208000005264 motor neuron disease Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- PHDSFVUKDSNSNP-UHFFFAOYSA-N n-[(3-imidazo[2,1-b][1,3]thiazol-6-ylphenyl)carbamothioyl]-3,4,5-trimethoxybenzamide Chemical compound COC1=C(OC)C(OC)=CC(C(=O)NC(=S)NC=2C=C(C=CC=2)C=2N=C3SC=CN3C=2)=C1 PHDSFVUKDSNSNP-UHFFFAOYSA-N 0.000 claims 2
- ZVRZMUZDUOXELB-UHFFFAOYSA-N n-[(3-indol-1-ylphenyl)carbamothioyl]-3,4,5-trimethoxybenzamide Chemical compound COC1=C(OC)C(OC)=CC(C(=O)NC(=S)NC=2C=C(C=CC=2)N2C3=CC=CC=C3C=C2)=C1 ZVRZMUZDUOXELB-UHFFFAOYSA-N 0.000 claims 2
- GGOOHMAHPJYVCU-UHFFFAOYSA-N n-[[3-(1h-indol-2-yl)phenyl]carbamothioyl]-3,4,5-trimethoxybenzamide Chemical compound COC1=C(OC)C(OC)=CC(C(=O)NC(=S)NC=2C=C(C=CC=2)C=2NC3=CC=CC=C3C=2)=C1 GGOOHMAHPJYVCU-UHFFFAOYSA-N 0.000 claims 2
- BGBLJBWRWCHKMK-UHFFFAOYSA-N n-[[3-(1h-indol-2-yl)phenyl]carbamoyl]-3,4,5-trimethoxybenzamide Chemical compound COC1=C(OC)C(OC)=CC(C(=O)NC(=O)NC=2C=C(C=CC=2)C=2NC3=CC=CC=C3C=2)=C1 BGBLJBWRWCHKMK-UHFFFAOYSA-N 0.000 claims 2
- 150000002825 nitriles Chemical class 0.000 claims 2
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 claims 2
- FDBYIYFVSAHJLY-UHFFFAOYSA-N resmetirom Chemical compound N1C(=O)C(C(C)C)=CC(OC=2C(=CC(=CC=2Cl)N2C(NC(=O)C(C#N)=N2)=O)Cl)=N1 FDBYIYFVSAHJLY-UHFFFAOYSA-N 0.000 claims 2
- 230000019491 signal transduction Effects 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 claims 1
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 claims 1
- GCTFTMWXZFLTRR-GFCCVEGCSA-N (2r)-2-amino-n-[3-(difluoromethoxy)-4-(1,3-oxazol-5-yl)phenyl]-4-methylpentanamide Chemical compound FC(F)OC1=CC(NC(=O)[C@H](N)CC(C)C)=CC=C1C1=CN=CO1 GCTFTMWXZFLTRR-GFCCVEGCSA-N 0.000 claims 1
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 claims 1
- FQMZXMVHHKXGTM-UHFFFAOYSA-N 2-(1-adamantyl)-n-[2-[2-(2-hydroxyethylamino)ethylamino]quinolin-5-yl]acetamide Chemical compound C1C(C2)CC(C3)CC2CC13CC(=O)NC1=CC=CC2=NC(NCCNCCO)=CC=C21 FQMZXMVHHKXGTM-UHFFFAOYSA-N 0.000 claims 1
- ZIBGOHCSAABMHS-UHFFFAOYSA-N 3,4,5-trimethoxy-n-[[3-[(4-phenylphenyl)carbamoylamino]phenyl]carbamoyl]benzamide Chemical compound COC1=C(OC)C(OC)=CC(C(=O)NC(=O)NC=2C=C(NC(=O)NC=3C=CC(=CC=3)C=3C=CC=CC=3)C=CC=2)=C1 ZIBGOHCSAABMHS-UHFFFAOYSA-N 0.000 claims 1
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 229940126657 Compound 17 Drugs 0.000 claims 1
- 229940127007 Compound 39 Drugs 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- 208000000172 Medulloblastoma Diseases 0.000 claims 1
- 206010029098 Neoplasm skin Diseases 0.000 claims 1
- 201000010133 Oligodendroglioma Diseases 0.000 claims 1
- 206010057846 Primitive neuroectodermal tumour Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 229940125877 compound 31 Drugs 0.000 claims 1
- 229940125900 compound 59 Drugs 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 1
- 208000010932 epithelial neoplasm Diseases 0.000 claims 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 230000003325 follicular Effects 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 206010027191 meningioma Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- DWAVRWHGZVNIKQ-UHFFFAOYSA-N n-[(3-imidazo[1,2-a]pyridin-2-ylphenyl)carbamothioyl]-3,4,5-trimethoxybenzamide Chemical compound COC1=C(OC)C(OC)=CC(C(=O)NC(=S)NC=2C=C(C=CC=2)C=2N=C3C=CC=CN3C=2)=C1 DWAVRWHGZVNIKQ-UHFFFAOYSA-N 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 claims 1
- 230000001537 neural effect Effects 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 1
- 229930192474 thiophene Natural products 0.000 claims 1
- 0 COc(cc(cc1OC)C(NC(Nc2cc(NC(c3ccccc3Cl)=O)ccc2)=S)=O)c1O* Chemical compound COc(cc(cc1OC)C(NC(Nc2cc(NC(c3ccccc3Cl)=O)ccc2)=S)=O)c1O* 0.000 description 4
- BFNOESVEKMASAA-UHFFFAOYSA-N CCOc(cc(cc1OCC)C(NC(Nc2cccc(NC(c3ccccc3)=O)c2)=S)=O)c1OCC Chemical compound CCOc(cc(cc1OCC)C(NC(Nc2cccc(NC(c3ccccc3)=O)c2)=S)=O)c1OCC BFNOESVEKMASAA-UHFFFAOYSA-N 0.000 description 2
- AZRGRNJRWFLKBH-UHFFFAOYSA-N COc(cc1)cc(OC)c1C(NC(Nc1cc(NC(c2ccccc2)=O)ccc1)=S)=O Chemical compound COc(cc1)cc(OC)c1C(NC(Nc1cc(NC(c2ccccc2)=O)ccc1)=S)=O AZRGRNJRWFLKBH-UHFFFAOYSA-N 0.000 description 2
- SDFCPIHDTKKVJX-UHFFFAOYSA-N COc1cc(C(NC(Nc2cccc(NC(Nc3ccccc3)=O)c2)=S)=O)cc(OC)c1OC Chemical compound COc1cc(C(NC(Nc2cccc(NC(Nc3ccccc3)=O)c2)=S)=O)cc(OC)c1OC SDFCPIHDTKKVJX-UHFFFAOYSA-N 0.000 description 2
- XNXPHKVTUGIUIP-UHFFFAOYSA-N COc(cc(cc1OC)C(NC(Nc(cc2)cc(C(Nc3ccccc3)=O)c2Cl)=S)=O)c1OC Chemical compound COc(cc(cc1OC)C(NC(Nc(cc2)cc(C(Nc3ccccc3)=O)c2Cl)=S)=O)c1OC XNXPHKVTUGIUIP-UHFFFAOYSA-N 0.000 description 1
- HSYJXXQMBVDCDP-UHFFFAOYSA-N COc(cc(cc1OC)C(NC(Nc(cc2)cc(NC(c3ccccc3)=O)c2Cl)=S)=O)c1OC Chemical compound COc(cc(cc1OC)C(NC(Nc(cc2)cc(NC(c3ccccc3)=O)c2Cl)=S)=O)c1OC HSYJXXQMBVDCDP-UHFFFAOYSA-N 0.000 description 1
- NQAUEOAYCLBHRR-UHFFFAOYSA-N Cc(ccc(NC(NC(c(cc1OC)cc(OC)c1OC)=O)=S)c1)c1NC(c1ccccc1)=O Chemical compound Cc(ccc(NC(NC(c(cc1OC)cc(OC)c1OC)=O)=S)c1)c1NC(c1ccccc1)=O NQAUEOAYCLBHRR-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0802302A FR2930552B1 (fr) | 2008-04-24 | 2008-04-24 | N-acylthiourees et n-acylurees inhibiteurs de la voie de signalisation des proteines hedgehog |
| FR0802302 | 2008-04-24 | ||
| PCT/FR2009/000442 WO2009130422A2 (fr) | 2008-04-24 | 2009-04-16 | N-acylthiourees et n-acylurees inhibiteurs de la voie de signalisation des proteines hedgehog |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011519832A JP2011519832A (ja) | 2011-07-14 |
| JP2011519832A5 true JP2011519832A5 (enExample) | 2012-05-31 |
| JP5819188B2 JP5819188B2 (ja) | 2015-11-18 |
Family
ID=40085488
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011505549A Expired - Fee Related JP5819188B2 (ja) | 2008-04-24 | 2009-04-16 | ヘッジホッグタンパク質シグナル伝達経路のｎ−アシルチオウレア及びｎ−アシルウレア阻害物質 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9073835B2 (enExample) |
| EP (1) | EP2291352B1 (enExample) |
| JP (1) | JP5819188B2 (enExample) |
| CA (1) | CA2722258C (enExample) |
| ES (1) | ES2651272T3 (enExample) |
| FR (1) | FR2930552B1 (enExample) |
| WO (1) | WO2009130422A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0619248Y2 (ja) | 1986-12-23 | 1994-05-18 | 旭硝子株式会社 | 読取センサ−ヘツド |
| EP2522341A1 (en) | 2011-05-13 | 2012-11-14 | Tragex Pharma | Pharmaceutical compositions comprising Neuropilin inhibitors, and their use for the prevention and/or treatment of angiogenic disorders and cancers |
| FR2980477B1 (fr) * | 2011-09-23 | 2013-10-18 | Centre Nat Rech Scient | Nouveaux composes modulateurs de la voie de signalisation des proteines hedgehog, leurs formes marquees, et applications |
| CA2863006A1 (en) * | 2012-01-27 | 2013-08-01 | National University Corporation University Of Toyama | Serine racemase inhibitor |
| JP6045828B2 (ja) * | 2012-07-11 | 2016-12-14 | 千葉県 | 抗癌剤 |
| CN104529905B (zh) * | 2014-12-09 | 2017-10-31 | 沈阳药科大学 | N‑3‑苯并咪唑酰双胺类衍生物及其制备方法与应用 |
| US10548908B2 (en) * | 2016-09-15 | 2020-02-04 | Nostopharma, LLC | Compositions and methods for preventing and treating heterotopic ossification and pathologic calcification |
| WO2018211007A1 (en) * | 2017-05-18 | 2018-11-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of mast cell diseases |
| CN112057443B (zh) * | 2019-10-12 | 2022-10-14 | 中国药科大学 | 苯磺酰胺类化合物的医药用途及其药物组合物 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4560770A (en) * | 1983-02-09 | 1985-12-24 | Ciba-Geigy Corporation | Pesticidal compositions based on N-pyrrolylphenyl-N'-benzoylurea compounds |
| GB9413975D0 (en) * | 1994-07-11 | 1994-08-31 | Fujisawa Pharmaceutical Co | New heterobicyclic derivatives |
| US6268387B1 (en) * | 1997-12-23 | 2001-07-31 | Warner-Lambert Company | Thiourea and benzamide compounds, compositions and methods of treating or preventing inflammatory diseases and atherosclerosis |
| AUPP873799A0 (en) * | 1999-02-17 | 1999-03-11 | Fujisawa Pharmaceutical Co., Ltd. | Pyridine compounds |
| DE10023430A1 (de) * | 2000-05-12 | 2001-11-15 | Bayer Ag | Substituierte N-Benzoyl-N'-(tetrazolylphenyl)-harnstoffe |
| TWI236474B (en) * | 2001-04-03 | 2005-07-21 | Telik Inc | Antagonists of MCP-1 function and methods of use thereof |
| PE20021091A1 (es) * | 2001-05-25 | 2003-02-04 | Aventis Pharma Gmbh | Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion |
| EA007339B1 (ru) * | 2001-07-27 | 2006-08-25 | Кьюэрис, Инк. | Медиаторы путей передачи сигналов генами hedgehog, содержащие их композиции и способы применения указанных веществ |
| US7262220B2 (en) * | 2002-07-11 | 2007-08-28 | Sanofi-Aventis Deutschland Gmbh | Urea- and urethane-substituted acylureas, process for their preparation and their use |
| DE50311923D1 (de) * | 2002-07-11 | 2009-10-29 | Sanofi Aventis Deutschland | Harnstoff- und urethan-substituierte acylharnstoffe, verfahren zu deren herstellung und deren verwendung als arzneimittel |
| AU2003249937A1 (en) * | 2002-07-12 | 2004-02-02 | Sanofi-Aventis Deutschland Gmbh | Heterocyclically substituted benzoylureas, method for their production and their use as medicaments |
| US7087761B2 (en) * | 2003-01-07 | 2006-08-08 | Hoffmann-La Roche Inc. | Cyclization process for substituted benzothiazole derivatives |
| US7179941B2 (en) * | 2003-01-23 | 2007-02-20 | Sanofi-Aventis Deutschland Gmbh | Carbonylamino-substituted acyl phenyl urea derivatives, process for their preparation and their use |
| NZ544331A (en) * | 2003-07-22 | 2010-03-26 | Arena Pharm Inc | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto |
| SI1558582T1 (sl) * | 2003-07-22 | 2006-06-30 | Arena Pharm Inc | Diaril in arilheteroaril secninski derivati kot modulatorji 5-HT2A serotoninskega receptorja, koristnega za profilakso in zdravljenje motenj, ki so znjim povezane |
| FR2879598B1 (fr) * | 2004-12-17 | 2007-03-30 | Sod Conseils Rech Applic | Inhibiteurs de phosphatases cdc25 |
| US20090081636A1 (en) * | 2005-04-11 | 2009-03-26 | Mingjun Huang | Pharmaceutical compositions for and methods of inhibiting HCV replication |
| ATE488232T1 (de) * | 2006-09-04 | 2010-12-15 | Univ Dundee | P53 aktivierende benzoylharnstoff- und benzoylthioharnstoff-verbindungen |
| EP2076513A1 (en) * | 2006-10-20 | 2009-07-08 | Irm Llc | Compositions and methods for modulating c-kit and pdgfr receptors |
-
2008
- 2008-04-24 FR FR0802302A patent/FR2930552B1/fr not_active Expired - Fee Related
-
2009
- 2009-04-16 EP EP09733789.3A patent/EP2291352B1/fr not_active Not-in-force
- 2009-04-16 WO PCT/FR2009/000442 patent/WO2009130422A2/fr not_active Ceased
- 2009-04-16 JP JP2011505549A patent/JP5819188B2/ja not_active Expired - Fee Related
- 2009-04-16 ES ES09733789.3T patent/ES2651272T3/es active Active
- 2009-04-16 CA CA2722258A patent/CA2722258C/fr not_active Expired - Fee Related
- 2009-04-16 US US12/988,975 patent/US9073835B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4422477B2 (ja) | ヘテロアリールスルホニル側鎖を有するアントラニル酸アミド、その製造方法、その医薬または診断助剤としての使用、およびこの化合物を含有する医薬製剤 | |
| JP4231295B2 (ja) | アントラニル酸アミド、その製造方法、抗不整脈剤としてのその使用、およびその医薬調製物 | |
| TWI333950B (en) | New benzimidazole derivatives | |
| JP5555868B2 (ja) | 新規なヒドロキサメート誘導体、その作製方法、及びこれを含有する薬学的組成物 | |
| JP4979583B2 (ja) | 新規のヒストンデアセチラーゼ阻害剤 | |
| WO2011145669A1 (ja) | アミド誘導体 | |
| CA2384974A1 (en) | Compounds and pharmaceutical compositions as cathepsin s inhibitors | |
| JP2005517672A5 (enExample) | ||
| JP2015514762A5 (enExample) | ||
| RU2013130878A (ru) | Гидроксилированные производные аминотриазола в качестве агонистов рецептора alx | |
| JP2013508384A5 (enExample) | ||
| CN109053630A (zh) | 一种苯并噻唑类衍生物及其用途 | |
| CN105218532A (zh) | 苯并三氮唑类化合物、制备方法和其医药用途 | |
| CN101759668A (zh) | 肉桂酰胺衍生物及其作为脑神经保护剂的应用 | |
| ES2715394T3 (es) | Nuevo antifúngico derivado de oxodihidropiridinacarbohidrazida | |
| JP5253174B2 (ja) | Ｎ−フェニルオキサミド酸誘導体 | |
| JP2004530650A5 (enExample) | ||
| EP4650002A1 (en) | Aniline-based modulators of the nuclear receptor tlx (nr2e1) | |
| CN103058959B (zh) | 一种n-(2-(4-甲基哌嗪-1-基)-5-甲酰苯基)酰胺类化合物及其应用 | |
| US12582719B2 (en) | Chimeric compounds and methods of managing neurological disorders or conditions | |
| JP2007530594A (ja) | 炎症及び免疫に関連する用途に用いられるアクリロニトリル誘導体 | |
| JP2006096739A (ja) | 置換又は無置換アミノ基を導入した４−ピリジルアルキルチオ基を有する新規環式化合物 | |
| EA201070381A1 (ru) | 5-арил-4,5-дигидро-(1н)-пиразолы в качестве агонистов каннабиоидного сврецептора | |
| KR101604627B1 (ko) | 신규한 메틸 2-(2-나프토일이미노-4-옥소티아졸리딘-5-일리딘)아세테이트 유도체 및 이의 항암 효과 | |
| JP2013520423A5 (enExample) |